Abstract
Diabetes is a prevalent disease which effects over 150 million people worldwide and there is a great medical need for new therapeutic agents to treat it. Inhibition of protein tyrosine phosphatase 1B (PTP1B) has emerged as a highly validated, attractive target for treatment of not only diabetes but also obesity. Discovery of small-molecule inhibitors has been pursued extensively in both academia and industry and a number of very potent and selective inhibitors have been identified. With X-ray crystallography, the binding interactions of several classes of inhibitors have been elucidated. This has resulted in significant progress in understanding important interactions between inhibitors and specific residues of PTP1B, which could help the design of future inhibitors. However, since the active site of PTP1B that most of these inhibitors bind to is highly hydrophilic, it remains a challenge to identify inhibitors with both excellent in vitro potency and drug-like physiochemical properties which would lead to good in vivo activities.
Keywords: protein phosphatase, protein tyrosine phosphatase 1b, ptp1b, ptp1b inhibitors, diabetes, anti-hyperglycemia, insulin resistance, obesity
Current Pharmaceutical Design
Title: Inhibition of Protein Tyrosine Phosphatase 1B as a Potential Treatment of Diabetes and Obesity
Volume: 10 Issue: 28
Author(s): Zhonghua Pei, Gang Liu, Thomas H. Lubben and Bruce G. Szczepankiewicz
Affiliation:
Keywords: protein phosphatase, protein tyrosine phosphatase 1b, ptp1b, ptp1b inhibitors, diabetes, anti-hyperglycemia, insulin resistance, obesity
Abstract: Diabetes is a prevalent disease which effects over 150 million people worldwide and there is a great medical need for new therapeutic agents to treat it. Inhibition of protein tyrosine phosphatase 1B (PTP1B) has emerged as a highly validated, attractive target for treatment of not only diabetes but also obesity. Discovery of small-molecule inhibitors has been pursued extensively in both academia and industry and a number of very potent and selective inhibitors have been identified. With X-ray crystallography, the binding interactions of several classes of inhibitors have been elucidated. This has resulted in significant progress in understanding important interactions between inhibitors and specific residues of PTP1B, which could help the design of future inhibitors. However, since the active site of PTP1B that most of these inhibitors bind to is highly hydrophilic, it remains a challenge to identify inhibitors with both excellent in vitro potency and drug-like physiochemical properties which would lead to good in vivo activities.
Export Options
About this article
Cite this article as:
Pei Zhonghua, Liu Gang, Lubben H. Thomas and Szczepankiewicz G. Bruce, Inhibition of Protein Tyrosine Phosphatase 1B as a Potential Treatment of Diabetes and Obesity, Current Pharmaceutical Design 2004; 10 (28) . https://dx.doi.org/10.2174/1381612043382954
DOI https://dx.doi.org/10.2174/1381612043382954 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cytochrome P450 and Steatosis
Current Drug Metabolism A Partial Failure of Membrane Protein Turnover May Cause Alzheimers Disease: A New Hypothesis
Current Alzheimer Research Gender Differences in Atrial Fibrillation: A Review of Epidemiology, Management, and Outcomes
Current Cardiology Reviews The Potential Role of Antioxidants in Metabolic Syndrome
Current Pharmaceutical Design The Role of microRNAs in the Initiation and Progression of Stable Atheromatous Plaque
Current Pharmaceutical Design Efficacy and Cardiovascular Safety of Sulfonylureas
Current Drug Safety The Modulation of Beneficial and/or Harmful Effects of Free Oxygen Radicals in the Context of Molecular Mechanisms Regarding Drug – PART I
Current Topics in Medicinal Chemistry Insulin Therapy, Insulin Resistance and Vascular Dysfunction
Current Vascular Pharmacology Diabetic Cardiomyopathy and Oxidative Stress: Role of Antioxidants
Cardiovascular & Hematological Agents in Medicinal Chemistry CoMFA, CoMSIA and HQSAR Analysis of 3-aryl-3-ethoxypropanoic Acid Derivatives as GPR40 Modulators
Current Drug Discovery Technologies Anti-Chlamydophila pneumoniae Antibodies as Associated Factor for Carotid Atherosclerosis in Patients with AIDS
Current HIV Research Glycation and Hypoxia: Two Key Factors for Adipose Tissue Dysfunction
Current Medicinal Chemistry Insulin-Like Growth Factor 1 Receptor Targeted Therapeutics: Novel Compounds and Novel Treatment Strategies for Cancer Medicine
Recent Patents on Anti-Cancer Drug Discovery Fetal Protein Restriction, Taurine and Islet Plasticity
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Modulation of Individual Susceptibility to the No-Reflow Phenomenon after Acute Myocardial Infarction
Current Pharmaceutical Design The Heat Stress Response and Diabetes: More Room for Mitochondrial Implication
Current Pharmaceutical Design Cell-Penetrating Peptides: Mechanisms and Applications
Current Pharmaceutical Design The Role of Vitamin D in Atherosclerosis Inflammation Revisited: More a Bystander than a Player?
Current Vascular Pharmacology Continuous Positive Airway Pressure Treatment in Patients with Sleep Apnoea: Does it Really Improve Glucose Metabolism?
Current Diabetes Reviews Molecular Targets for Promoting Wound Healing in Diabetes
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued)